Simcere Pharmaceutical Group Ltd
HKEX:2096

Watchlist Manager
Simcere Pharmaceutical Group Ltd Logo
Simcere Pharmaceutical Group Ltd
HKEX:2096
Watchlist
Price: 6.61 HKD -2.51% Market Closed
Market Cap: 16.7B HKD
Have any thoughts about
Simcere Pharmaceutical Group Ltd?
Write Note

Intrinsic Value

The intrinsic value of one Simcere Pharmaceutical Group Ltd stock under the Base Case scenario is 10.72 HKD. Compared to the current market price of 6.61 HKD, Simcere Pharmaceutical Group Ltd is Undervalued by 38%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

Intrinsic Value
10.72 HKD
Undervaluation 38%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation Backtest
Simcere Pharmaceutical Group Ltd

Backtest Intrinsic Value
Dive into the past to invest in the future

Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.

Start backtest now and learn if your stock is truly undervalued or overvalued!

Run Backtest
Backtest Conclusion
Very Attractive
Current Valuation
+45%
Avg Valuation
-12%
Worst Valuation
-49%
Best Valuation
+45%

Stock is trading at its lowest valuation over the past 5 years.

Backtest Example
Register to View Results
Register to View Results

To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.

Backtest Unavailable

The backtest for Simcere Pharmaceutical Group Ltd cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.

Backtest In Progress...
Backtest In Progress...
How do you feel about Simcere Pharmaceutical Group Ltd?
Bearish
Neutral
Bullish

Fundamental Analysis

Company Quality
No Indicators Selected
Select Indicators

Select up to 3 indicators:

Insider Trading
0-3
Months
0-6
Months
0-12
Months
0-36
Months
No Periods Selected
Select Periods

Select up to 2 periods:

Investment Journal
AI Assistant
AI Assistant
Ask me anything about Simcere Pharmaceutical Group Ltd

Provide an overview of the primary business activities
of Simcere Pharmaceutical Group Ltd.

What unique competitive advantages
does Simcere Pharmaceutical Group Ltd hold over its rivals?

What risks and challenges
does Simcere Pharmaceutical Group Ltd face in the near future?

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Simcere Pharmaceutical Group Ltd.

Provide P/S
for Simcere Pharmaceutical Group Ltd.

Provide P/E
for Simcere Pharmaceutical Group Ltd.

Provide P/OCF
for Simcere Pharmaceutical Group Ltd.

Provide P/FCFE
for Simcere Pharmaceutical Group Ltd.

Provide P/B
for Simcere Pharmaceutical Group Ltd.

Provide EV/S
for Simcere Pharmaceutical Group Ltd.

Provide EV/GP
for Simcere Pharmaceutical Group Ltd.

Provide EV/EBITDA
for Simcere Pharmaceutical Group Ltd.

Provide EV/EBIT
for Simcere Pharmaceutical Group Ltd.

Provide EV/OCF
for Simcere Pharmaceutical Group Ltd.

Provide EV/FCFF
for Simcere Pharmaceutical Group Ltd.

Provide EV/IC
for Simcere Pharmaceutical Group Ltd.

Show me price targets
for Simcere Pharmaceutical Group Ltd made by professional analysts.

What are the Revenue projections
for Simcere Pharmaceutical Group Ltd?

How accurate were the past Revenue estimates
for Simcere Pharmaceutical Group Ltd?

What are the Net Income projections
for Simcere Pharmaceutical Group Ltd?

How accurate were the past Net Income estimates
for Simcere Pharmaceutical Group Ltd?

What are the EPS projections
for Simcere Pharmaceutical Group Ltd?

How accurate were the past EPS estimates
for Simcere Pharmaceutical Group Ltd?

What are the EBIT projections
for Simcere Pharmaceutical Group Ltd?

How accurate were the past EBIT estimates
for Simcere Pharmaceutical Group Ltd?

Compare the revenue forecasts
for Simcere Pharmaceutical Group Ltd with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Simcere Pharmaceutical Group Ltd and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Simcere Pharmaceutical Group Ltd against its competitors.

Analyze the profit margins
(gross, operating, and net) of Simcere Pharmaceutical Group Ltd compared to its peers.

Compare the P/E ratios
of Simcere Pharmaceutical Group Ltd against its peers.

Discuss the investment returns and shareholder value creation
comparing Simcere Pharmaceutical Group Ltd with its peers.

Analyze the financial leverage
of Simcere Pharmaceutical Group Ltd compared to its main competitors.

Show all profitability ratios
for Simcere Pharmaceutical Group Ltd.

Provide ROE
for Simcere Pharmaceutical Group Ltd.

Provide ROA
for Simcere Pharmaceutical Group Ltd.

Provide ROIC
for Simcere Pharmaceutical Group Ltd.

Provide ROCE
for Simcere Pharmaceutical Group Ltd.

Provide Gross Margin
for Simcere Pharmaceutical Group Ltd.

Provide Operating Margin
for Simcere Pharmaceutical Group Ltd.

Provide Net Margin
for Simcere Pharmaceutical Group Ltd.

Provide FCF Margin
for Simcere Pharmaceutical Group Ltd.

Show all solvency ratios
for Simcere Pharmaceutical Group Ltd.

Provide D/E Ratio
for Simcere Pharmaceutical Group Ltd.

Provide D/A Ratio
for Simcere Pharmaceutical Group Ltd.

Provide Interest Coverage Ratio
for Simcere Pharmaceutical Group Ltd.

Provide Altman Z-Score Ratio
for Simcere Pharmaceutical Group Ltd.

Provide Quick Ratio
for Simcere Pharmaceutical Group Ltd.

Provide Current Ratio
for Simcere Pharmaceutical Group Ltd.

Provide Cash Ratio
for Simcere Pharmaceutical Group Ltd.

What is the historical Revenue growth
over the last 5 years for Simcere Pharmaceutical Group Ltd?

What is the historical Net Income growth
over the last 5 years for Simcere Pharmaceutical Group Ltd?

What is the current Free Cash Flow
of Simcere Pharmaceutical Group Ltd?

Discuss the annual earnings per share (EPS)
trend over the past five years for Simcere Pharmaceutical Group Ltd.

Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Revenue & Expenses Breakdown
Simcere Pharmaceutical Group Ltd

Balance Sheet Decomposition
Simcere Pharmaceutical Group Ltd

Current Assets 6.4B
Cash & Short-Term Investments 3.1B
Receivables 2.5B
Other Current Assets 853.5m
Non-Current Assets 5.3B
Long-Term Investments 1.4B
PP&E 2.2B
Intangibles 1.1B
Other Non-Current Assets 516.6m
Current Liabilities 3.1B
Accounts Payable 355.9m
Short-Term Debt 993.8m
Other Current Liabilities 1.7B
Non-Current Liabilities 1.7B
Long-Term Debt 103.6m
Other Non-Current Liabilities 1.6B
Efficiency

Earnings Waterfall
Simcere Pharmaceutical Group Ltd

Revenue
6.3B CNY
Cost of Revenue
-1.5B CNY
Gross Profit
4.9B CNY
Operating Expenses
-3.9B CNY
Operating Income
941.5m CNY
Other Expenses
-2B CNY
Net Income
-1.1B CNY

Free Cash Flow Analysis
Simcere Pharmaceutical Group Ltd

Last Value
3-Years Average
FCF Margin
Conversion Rate
Fundamental Scores

Profitability Score
Profitability Due Diligence

Simcere Pharmaceutical Group Ltd's profitability score is 52/100. The higher the profitability score, the more profitable the company is.

Positive Gross Profit
Positive 3-Year Average ROE
Positive 3-Years Revenue Growth
Negative Net Income
52/100
Profitability
Score

Simcere Pharmaceutical Group Ltd's profitability score is 52/100. The higher the profitability score, the more profitable the company is.

Solvency Score
Solvency Due Diligence

Simcere Pharmaceutical Group Ltd's solvency score is 69/100. The higher the solvency score, the more solvent the company is.

Low D/E
Negative Net Debt
Long-Term Solvency
High Altman Z-Score
69/100
Solvency
Score

Simcere Pharmaceutical Group Ltd's solvency score is 69/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

Price Targets Summary
Simcere Pharmaceutical Group Ltd

Wall Street analysts forecast Simcere Pharmaceutical Group Ltd stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for Simcere Pharmaceutical Group Ltd is 8.98 HKD with a low forecast of 7.47 HKD and a high forecast of 12.08 HKD.

Lowest
Price Target
7.47 HKD
13% Upside
Average
Price Target
8.98 HKD
36% Upside
Highest
Price Target
12.08 HKD
83% Upside
View Analyst Estimates
View Analyst Estimates
Want to learn more about Wall St estimates for Simcere Pharmaceutical Group Ltd?

Click here to dive deeper.

Dividends

Dividend Yield
Lowest
Average
Highest
Dividend Per Share
N/A
Growth 3Y
Growth 5Y
Growth 10Y
Dividend Safety Score
Very
Unsafe
Unsafe
Safe
Very
Safe
0
25
50
75
100
Shareholder Yield

Current shareholder yield for Simcere Pharmaceutical Group Ltd is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
Lowest
Average
Highest
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Profile

Simcere Pharmaceutical Group Ltd Logo
Simcere Pharmaceutical Group Ltd

Country

China

Industry

Pharmaceuticals

Market Cap

16.8B HKD

Dividend Yield

2.66%

Description

Simcere Pharmaceutical Group Ltd. engages in the research, development, manufacturing, and sale of pharmaceutical products. The company is headquartered in Nanjing, Jiangsu. The company went IPO on 2020-10-27. The firm's main products are generic drugs, including Bicun used for central nervous system diseases, Jepaso and Jiebaili used for oncology, as well as Yingtaiqing used for autoimmune diseases. The firm also produces innovative drugs, such as Endostar used for oncology. The firm is also involved in providing promotion services for third-party drugs sold by medical institutions.

Contact

JIANGSU
Nanjing
No. 699-18, Xuanwu Avenue, Xuanwu District
www.simcere.com

IPO

2020-10-27

Employees

6 204

Officers

Co-Founder, Chairman & CEO
Mr. Jinsheng Ren
CFO, Joint Company Secretary & Executive Director
Mr. Yushan Wan
Executive Director
Mr. Renhong Tang Ph.D.
VP & Executive Director
Ms. Xi Wang
Chief Investment Officer
Mr. Gaobo Zhou
Vice President of Marketing
Mr. Quanfu Feng
Show More
Senior VP & Chief Scientific Officer of Simcere Zaiming
Dr. Tamas Oravecz Ph.D.
Senior VP & Chief Medical Officer
Dr. Aik Han Goh
Senior Vice President
Mr. Wang John
Senior VP & Chief Medical Officer of Simcere Zaiming
Dr. Yongyu Wang
Show Less

See Also

Discover More
What is the Intrinsic Value of one Simcere Pharmaceutical Group Ltd stock?

The intrinsic value of one Simcere Pharmaceutical Group Ltd stock under the Base Case scenario is 10.72 HKD.

Is Simcere Pharmaceutical Group Ltd stock undervalued or overvalued?

Compared to the current market price of 6.61 HKD, Simcere Pharmaceutical Group Ltd is Undervalued by 38%.

Back to Top